While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.
Mylan pushed the blame for high EpiPen prices onto PBMs Thursday, causing share prices to dip. Analysts say investors were mislead.
To help seal pharma deals, buyers are offering sellers the prospect of extra cash for yet to be developed drugs, but investors will often find these "contingent value rights" worthless.
The drugmaker could be at risk as regulators begin to crack down on price hikes, Andrew Left says.
The company is under public scrutiny, and has lost more than 12% of its share price so far this week.
After Mylan raised the price of its EpiPen by 400 percent, sparking a wave of controversy, the company now saying it will offer a savings card worth $300 to users.
Short-seller Andrew Left says Mallinckrodt has long been gaming the system on its Acthar Gel drug.
Clinton hammers a whole sector by criticizing an increase in Epipens.
Shares of Gilead Sciences were lower Wednesday after Leerink cut its price target on the shares.